Search results
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 1 day agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Sperm: Common Questions About Quantity and Cell Composition
Verywell Health via Yahoo News· 6 days agoAround 300 million sperm are ejected with each ejaculation. This many are needed because only around...
Christina Applegate says she's in a 'real depression' due to MS symptoms: 'Kind of scaring me'
TODAY via Yahoo News· 4 days agoChristina Applegate's revealed her multiple sclerosis (MS) diagnosis publicly in 2021. Here's...
Elahere and dosage: Strength, form, when it's given, and more
Medical News Today· 3 days agoElahere (mirvetuximab soravtansine-gynx) is a brand-name drug prescribed for certain types of...
Crisis pregnancy centers: a masterclass in deceptive marketing | Opinion
NJ.com· 7 days agoLast weekend, the South Jersey Times Editorial Board, which is part of NJ Advance Media, wrote a...
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
Reuters· 3 days ago, opens new tab said on Thursday its therapy to treat patients with a type of ovarian cancer has met...
AbbVie reports positive Phase II ovarian cancer trial data
Clinical Trials Arena via Yahoo Finance· 2 days agoCurrently, mirvetuximab soravtansine is approved in the US under the brand name ELAHERE for treating...
Column: Despite benefits of over-the-county birth control pills, there are also risks
Gannett via AOL· 3 days agoOpill may also slow down the movement of the ovum through the fallopian tubes or affect endometrial...
Texas Supreme Court Rules Against Women Denied Abortions Despite Pregnancy Complications
Teen Vogue via Yahoo News· 5 days agoAfter she developed sepsis as a result of her miscarriage, doctors induced an abortion and Zurawski...
Endometriosis tormented her every month - and killed her aged 38
BBC via Yahoo News· 3 days agoThat was because of the lack of local facilities specialising in the treatment of endometriosis....